1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Diabetes World Drug Market Report 2016-2026

Diabetes World Drug Market Report 2016-2026

  • June 2016
  • 258 pages
  • ID: 4031805
  • Format: PDF
  • By Visiongain


Table of Contents

Report Details
Treating diabetes – benefit your influence by finding new R&D trends and sales prospects
Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities.

Visiongain’s updated report forecasts those revenues to 2026 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what’s possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines’ predicted revenue.

Forecasts to 2026 and other analyses explain and predict the diabetes treatment market
Why miss crucial data that you need? Why struggle to find information? Instead our report gives you revenue forecasts to 2026, also with recent results, growth rates, market shares and discussions.

Our 258 page report provides 76 tables and 141 figures, and an interview with Professor Mark Baker, Director of the Centre for Clinical Practice (CCP) at the National Institute of Healthcare Excellence.

Our work’s purpose is to predict that industry’s future, helping your research, analyses and decisions. See how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities exist.

The following sections show how our new investigation benefits your work.

Forecasting of the world diabetes drugs market and its segments – what does the future hold?
What are the secrets of the industry's progress? Where’s it heading? Discover in our report overall world revenue prediction to 2026 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2026 for nine therapeutic submarkets at world level:
- Human insulins and analogues
- Dipeptidyl peptidase-4 inhibitors (DPP-4)
- Biguanides
- Glucagon-like peptide-1 receptor agonists (GLP-1)
- Sulfonylureas.

And these treatment categories:
- Thiazolidinediones
- Alpha-glucosidase inhibitors
- Meglitinides
- Sodium-glucose co-transporter-2 inhibitors (SGLT2)
- Other agents (grouped).

You can assess the outlook for revenue expansion, learning where you can profit. Find the diabetes market size from 2016-2026. You can investigate the competition and rising sales. And you will examine technological, clinical and commercial possibilities.

Also you will find top medicines’ revenue potentials.

Predictions of leading products’ sales – see what’s possible, and where you can gain
How will individual drugs for elevated blood sugar perform to 2026 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:
- Lantus
- Januvia
- NovoLog and NovoMix
- Levemir
- Humalog
- Victoza
- Janumet
- Humulin.

There you will find drugs and the years with highest predicted sales. You can also examine competitors. So discover what’s happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

Our work also gives geographical sales predictions.

National markets – what is the outlook for treatment demand and revenues?
In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2016 to 2026. See where, how and what’s possible.

Our analyses show you individual revenue forecasts to 2026 for 11 national markets:
- United States (US)
- Japan
- EU leaders – Germany, France, the UK, Italy and Spain (EU5)
- BRIC nations – Brazil, Russia, India and China.

There you can explore the market progress, needs and opportunities. What events will change that market and the outlook for payers and patients? Our work shows you, discussing the trends and demands.

Events affecting developers, producers and sellers of those metabolic treatments
Our report also explains issues, forces and events affecting the antidiabetics industry and market from 2016, including these influences:
- Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates
- Governmental investment and collaboration between pharmaceutical companies
- Combination therapies for type 2 diabetes
- Competition from biosimilars and generic drugs – approvals and product launches.

And these issues are also assessed, among others:
- Disease incidence and prevalence
- Risk factors – obesity and pre-diabetes, related metabolic conditions
- Drug delivery – technologies for introducing insulin and oral drugs
- New classes of antidiabetic medications and regulatory challenges
- Type 1 diabetes vaccine – new treatment approaches, including disease prevention.

Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you can investigate what stimulates and restrains that biopharma, affecting its results. Also you will see the prospects for small-molecule therapies.

Analysis of firms and potential for rising sales – what overall revenues are possible?
What happens next? Our study predicts the world market will rise to $75bn in 2020, with high, expanding revenues from 2016 to 2026. Discover what’s possible.

Our analysis covers organisations shaping that industry:
- Novo Nordisk
- Eli Lilly
- Novartis
- AstraZeneca
- Merck & Co.

We also investigate these leading companies, among other firms, including specialists in metabolic disorders:
- Boehringer Ingelheim
- Takeda
- Sanofi
- Bayer
- Pfizer.

From 2016, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.

Ways Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2016-2026 helps
In particular, our new investigation gives this knowledge to benefit your work:
- Antidiabetic drug revenues to 2026 at overall world level, for 9 therapeutic submarkets and 31 products – assess outlooks for production, marketing and sales
- Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for demand and revenue potentials
- Prospects for established competitors, rising companies and new entrants – explore portfolios, opinions, results, strategies, technologies and outlooks for success
- Review of R&D pipelines – examine progress in research and development, finding technological and medical prospects
- Analysis of what stimulates and restrains that industry and market – gauge challenges and strengths, helping you compete, gain advantages and succeed.

Our new study, produced in-house by our UK-based analysts, helps your knowledge and authority.

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


  • $ 2500
  • February 2020

KEY FINDINGSThe global varicella live vaccine market is estimated to grow and record a CAGR of 5.78% during the forecast period of 2020-2028. The factors fueling the market growth are the rise in the awareness ...

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020, provides an ...

Cholera - Pipeline Review, H1 2020

Cholera - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Cholera - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H1 2020, provides an overview of the Cholera (Infectious Disease) pipeline ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • February 2020
    5 pages
  • Therapy  

  • United Kingdom  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2020
    7 pages
  • Hormone  



  • Pakistan  

    United States  


View report >

Therapy Market in the US

  • February 2020
    101 pages
  • Therapy  

    Cystic Fibrosis  


  • United States  

View report >

Analgesic Market 5 days ago

Therapy Market 6 days ago


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on